Hematologic Oncology

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss unmet needs to address in the management of PNH.